Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm to Present at the 15th Annual BIO Investor Forum

NEWTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Executive Vice President,...
October 05, 2016 06:18 ET | Source: Karyopharm Therapeutics

Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting

- Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers - - 49% Disease Control Rate Observed in Ovarian...
September 29, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Publishes Preclinical Data in Nature Demonstrating Selinexor’s Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

- Nuclear Transport Machinery Identified as a Necessary and Universal Driver of KRAS-mutant Cell Survival - - Inhibition of the Nuclear Export Protein XPO1 Promoted Apoptosis across a Panel...
September 28, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication

- XPO1 Inhibition Significantly Reduced Tumor Burden in Platinum Sensitive and Resistant Ovarian Cancer Models- - Company to Report Updated Phase 2 SIGN Data of Selinexor in Gynecological...
September 12, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development

NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD,...
September 06, 2016 07:00 ET | Source: Karyopharm Therapeutics

Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma

- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease - - Expanding Phase 2b STORM Study...
August 30, 2016 12:14 ET | Source: Karyopharm Therapeutics

Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans

NEWTON, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line...
August 04, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress

Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to Report Top-Line Data from STORM and STOMP Studies in Relapsed/Refractory Multiple Myeloma and...
August 03, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm to Present at Upcoming Investor Conferences

NEWTON, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
July 28, 2016 08:00 ET | Source: Karyopharm Therapeutics

Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016

NEWTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016...